Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
A group of former leaders from health comms giant Inizio Evoke have come together to launch Flex Marketing, a new agency ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts a | ...
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results